Selected research
Industry Growth & Trends
Global Hormone Refractory Prostate Cancer (HRPCA) Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Hormone Refractory Prostate Cancer (HRPCA) market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Hormone Refractory Prostate Cancer (HRPCA) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Hormone Refractory Prostate Cancer (HRPCA) is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Hormone Refractory Prostate Cancer (HRPCA) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Hormone Refractory Prostate Cancer (HRPCA) market include Sanofi S.A, Johnson & Johnson, Astellas Inc and Dendreon Corporation, Bayer AG, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Hormone Refractory Prostate Cancer (HRPCA) market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Hormone Refractory Prostate Cancer (HRPCA) market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Hormone Refractory Prostate Cancer (HRPCA) market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Hormone Refractory Prostate Cancer (HRPCA).
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Hormone Refractory Prostate Cancer (HRPCA) market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Hormone Refractory Prostate Cancer (HRPCA) Market by Company
Sanofi S.A
Johnson & Johnson
Astellas Inc
Dendreon Corporation, Bayer AG
Hormone Refractory Prostate Cancer (HRPCA) Segment by Type
Vaccines
Cytotoxic Agents
Anti-Androgens
Radio-Pharmaceuticals
Hormone Refractory Prostate Cancer (HRPCA) Segment by Application
Specialty Clinics
Hospitals
Ambulatory Surgical Centers
Others
Hormone Refractory Prostate Cancer (HRPCA) Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hormone Refractory Prostate Cancer (HRPCA) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Hormone Refractory Prostate Cancer (HRPCA) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hormone Refractory Prostate Cancer (HRPCA).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Hormone Refractory Prostate Cancer (HRPCA) companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Vaccines
- Cytotoxic Agents
- Anti-Androgens
- Radio-Pharmaceuticals
Applications
- Specialty Clinics
- Hospitals
- Ambulatory Surgical Centers
- Others
Companies covered
- Sanofi S.A
- Johnson & Johnson
- Astellas Inc
- Dendreon Corporation, Bayer AG
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2021-2032)
- 1.4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2021-2026)
- 1.4.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2027-2032)
- 1.5 Key Regions Hormone Refractory Prostate Cancer (HRPCA) Market Size (2021-2032)
- 1.5.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2021-2032)
- 1.5.4 South America Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2021-2032)
2 Hormone Refractory Prostate Cancer (HRPCA) Market by Type
- 2.1 Type Introduction
- 2.1.1 Vaccines
- 2.1.2 Cytotoxic Agents
- 2.1.3 Anti-Androgens
- 2.1.4 Radio-Pharmaceuticals
- 2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type
- 2.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Overview by Type (2021-2032)
- 2.2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Forecasted by Type (2027-2032)
- 2.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Regions
- 2.3.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Hormone Refractory Prostate Cancer (HRPCA) Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Breakdown by Type (2021-2026)
3 Hormone Refractory Prostate Cancer (HRPCA) Market by Application
- 3.1 Type Introduction
- 3.1.1 Specialty Clinics
- 3.1.2 Hospitals
- 3.1.3 Ambulatory Surgical Centers
- 3.1.4 Others
- 3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application
- 3.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Overview by Application (2021-2032)
- 3.2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Forecasted by Application (2027-2032)
- 3.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Regions
- 3.3.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Hormone Refractory Prostate Cancer (HRPCA) Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Hormone Refractory Prostate Cancer (HRPCA) Industry Trends
- 4.2 Hormone Refractory Prostate Cancer (HRPCA) Industry Drivers
- 4.3 Hormone Refractory Prostate Cancer (HRPCA) Industry Opportunities and Challenges
- 4.4 Hormone Refractory Prostate Cancer (HRPCA) Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Hormone Refractory Prostate Cancer (HRPCA) Revenue (2021-2026)
- 5.2 Global Hormone Refractory Prostate Cancer (HRPCA) Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Hormone Refractory Prostate Cancer (HRPCA) Key Company Headquarters & Area Served
- 5.4 Global Hormone Refractory Prostate Cancer (HRPCA) Company, Product Type & Application
- 5.5 Global Hormone Refractory Prostate Cancer (HRPCA) Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Hormone Refractory Prostate Cancer (HRPCA) Players Market Share by Revenue in 2025
- 5.6.3 2025 Hormone Refractory Prostate Cancer (HRPCA) Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Sanofi S.A
- 6.1.1 Sanofi S.A Company Information
- 6.1.2 Sanofi S.A Business Overview
- 6.1.3 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
- 6.1.5 Sanofi S.A Recent Developments
- 6.2 Johnson & Johnson
- 6.2.1 Johnson & Johnson Company Information
- 6.2.2 Johnson & Johnson Business Overview
- 6.2.3 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
- 6.2.5 Johnson & Johnson Recent Developments
- 6.3 Astellas Inc
- 6.3.1 Astellas Inc Company Information
- 6.3.2 Astellas Inc Business Overview
- 6.3.3 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
- 6.3.5 Astellas Inc Recent Developments
- 6.4 Dendreon Corporation, Bayer AG
- 6.4.1 Dendreon Corporation, Bayer AG Company Information
- 6.4.2 Dendreon Corporation, Bayer AG Business Overview
- 6.4.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product Portfolio
- 6.4.5 Dendreon Corporation, Bayer AG Recent Developments
7 North America
- 7.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021-2026)
- 7.3 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021-2026)
- 8.3 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021-2026)
- 10.3 South America Hormone Refractory Prostate Cancer (HRPCA) Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst